Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-15 Enhanced Engineered NK Cells in Refractory Relapsed/Metastatic Solid Tumors
NCT07621471Phase 1Recruiting
- Sponsor
- Genovn Therapeutics
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of interleukin-15 enhanced engineered natural killer cells in solid tumor, sponsored by Genovn Therapeutics. Primary endpoint: Incidence of Dose-Limiting Toxicity at 28 days. Started Oct 2026; status: recruiting.
02
Drugs
interleukin-15 enhanced engineered natural killer cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07621471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621471.